TW202245742A - 預防、治療或改善潰瘍性結腸炎的方法 - Google Patents

預防、治療或改善潰瘍性結腸炎的方法 Download PDF

Info

Publication number
TW202245742A
TW202245742A TW111104482A TW111104482A TW202245742A TW 202245742 A TW202245742 A TW 202245742A TW 111104482 A TW111104482 A TW 111104482A TW 111104482 A TW111104482 A TW 111104482A TW 202245742 A TW202245742 A TW 202245742A
Authority
TW
Taiwan
Prior art keywords
dose
subject
amimod
administration period
administering
Prior art date
Application number
TW111104482A
Other languages
English (en)
Chinese (zh)
Inventor
李智敏
尼爾 斯拉金
以斯拉 R 洛
澤布 海曼森
Original Assignee
愛爾蘭商博士健康愛爾蘭有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商博士健康愛爾蘭有限公司 filed Critical 愛爾蘭商博士健康愛爾蘭有限公司
Publication of TW202245742A publication Critical patent/TW202245742A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Cereal-Derived Products (AREA)
TW111104482A 2021-02-08 2022-02-08 預防、治療或改善潰瘍性結腸炎的方法 TW202245742A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163147060P 2021-02-08 2021-02-08
US63/147,060 2021-02-08

Publications (1)

Publication Number Publication Date
TW202245742A true TW202245742A (zh) 2022-12-01

Family

ID=80447376

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111104482A TW202245742A (zh) 2021-02-08 2022-02-08 預防、治療或改善潰瘍性結腸炎的方法

Country Status (9)

Country Link
US (1) US20240299318A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288041A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506041A (cg-RX-API-DMAC7.html)
CN (1) CN116940350A (cg-RX-API-DMAC7.html)
AU (1) AU2022217475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207440A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009249A (cg-RX-API-DMAC7.html)
TW (1) TW202245742A (cg-RX-API-DMAC7.html)
WO (1) WO2022167690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134072A1 (en) * 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
MA40775A (fr) * 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
US20180228778A1 (en) * 2015-08-11 2018-08-16 Akaal Pharma Pty Ltd Compositions comprising s1p receptor modulators
WO2018237379A2 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN113613640B (zh) * 2018-09-08 2024-11-29 谭文 肾上腺素能β2受体激动剂R-对映体在治疗炎症性肠病及其肠外疾病的新应用
US20220390464A1 (en) * 2019-07-30 2022-12-08 Children's Medical Center Corporation Methods and compositions for characterizing inflammatory bowel disease

Also Published As

Publication number Publication date
JP2024506041A (ja) 2024-02-08
EP4288041A1 (en) 2023-12-13
AU2022217475A1 (en) 2023-08-24
CN116940350A (zh) 2023-10-24
WO2022167690A1 (en) 2022-08-11
MX2023009249A (es) 2023-10-23
CA3207440A1 (en) 2022-08-11
US20240299318A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
JP6309454B2 (ja) 癌の併用処置
JP6244497B1 (ja) 選択的s1p1レセプターアゴニストの投与法
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
EP3294283B1 (en) Sacubitril-valsartan dosage regimen for treating heart failure
CZ292002B6 (cs) Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců
CN106456626A (zh) 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物
JP2019504096A (ja) サクビトリルおよびバルサルタンの組合せの新規使用
JP7701757B2 (ja) タウロデオキシコール酸またはその薬学的に許容される塩を有効成分として含む新型コロナウイルス感染症(covid-19)の治療用組成物
WO2023231730A2 (zh) 使用mazdutide的治疗方法
KR20200062241A (ko) 시포니모드의 투여 요법
JP2025041746A (ja) 9-アミノメチルミノサイクリン化合物及び市中感染型細菌性肺炎(cabp)の治療におけるその使用
US20240299318A1 (en) Amiselimod for preventing, treating or ameliorating ulcerative colitis
TW202525278A (zh) 治療慢性腎病及高血壓之方法
US20230151093A1 (en) Methods of treating immune mediated pulmonary injury
HK40094222A (en) Amiselimod for preventing, treating, or ameliorating ulcerative colitis
EA051860B1 (ru) Способ профилактики, лечения или облегчения язвенного колита
JP2025505187A (ja) 体重減少の方法および骨格筋量を保存する方法
WO2025134072A1 (en) Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
WO2021224494A1 (en) New treatments of viral infections
CN111000847B (zh) 一种治疗肺纤维化的药物制剂及其用途
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
JP2025505632A (ja) 上昇したHbA1cを有する対象における体重減少の方法